IP Library Granted Patent US 11,090,311
Granted Patent B2
US 11,090,311 · App. 16/918,378 · Granted Aug 17, 2021

Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

Inventors: Thomas J. Slaga (San Antonio, TX); Jacob Junco (San Antonio, TX); Huiyun Liang (San Antonio, TX); Sara Reyna (San Antonio, TX)
Assignee: Board of Regents, the University of Texas System
A61K31/56A61K9/0053A61K31/05A61K31/19A61P3/04A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,090,311
App. No.
16/918,378
Granted
Aug 17, 2021
Kind
B2
Abstract

Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.

Claims (21)

1. A nutritional supplement comprising:

ursolic acid and resveratrol in a ratio of ursolic acid to resveratrol of 3:1 to 1:3,

wherein the nutritional supplement is formulated for oral consumption as a tablet, a capsule, a concentrate, a powder, a drink, or a food, and

wherein the nutritional supplement is in addition to food in a normal diet, and

wherein the nutritional supplement is formulated to be consumed one or more times per day.

2. The nutritional supplement of claim 1 , wherein the effective amount of the nutritional supplement comprises 50 to 600 mg of ursolic acid.

3. The nutritional supplement of claim 1 , wherein the effective amount of the nutritional supplement comprises 200 mg of ursolic acid.

4. The nutritional supplement of claim 1 , wherein the effective amount of the nutritional supplement comprises 50 to 600 mg resveratrol.

5. The nutritional supplement of claim 1 , wherein the effective amount of the nutritional supplement comprises 600 mg of resveratrol.

6. The nutritional supplement of claim 1 , wherein the effective amount of the nutritional supplement comprises 200 mg of ursolic acid and 600 mg of resveratrol.

7. The nutritional supplement of claim 1 , wherein the effective amount of the nutritional supplement comprises 100 mg of ursolic acid and 200 mg of resveratrol.

8. The nutritional supplement of claim 1 , wherein the nutritional supplement comprises one or more of a preserving, an emulsifying, or a dispersing agent.

9. The nutritional supplement of claim 1 , wherein the nutritional supplement comprises one or more of a filler or extender, a binder, a humectant, a disintegrating agent, solution retarder, absorption accelerator, wetting agent, an adsorbent, lubricant, or buffering agent.

10. The nutritional supplement of claim 9 , wherein the filler is starch, lactose, sucrose, mannitol, or silicic acid.

11. The nutritional supplement of claim 9 , wherein the binder is carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, or acacia.

12. The nutritional supplement of claim 9 , wherein the humectant is glycerol.

13. The nutritional supplement of claim 9 , wherein the disintegrating agent is agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, complex silicates, or sodium carbonate.

14. The nutritional supplement of claim 9 , wherein the solution retarder is paraffin.

15. The nutritional supplement of claim 9 wherein the wetting agent is cetyl alcohol or glycerol monostearate.

16. The nutritional supplement of claim 9 , wherein the lubricant is talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof.

17. The nutritional supplement of claim 1 , wherein the food comprises a baked good, chocolate, caramel, cookie, or bar.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2020
From: SLAGA, THOMAS J.; JUNCO, JACOB; LIANG, HUIYUN; REYNA, SARA
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 053116/0130 →
Continuity (5)
Continuation 16813017 · Mar 9, 2020
Continuation 16221094 · Dec 14, 2018
Continuation 15308427
Provisional Application 61988859 · May 5, 2014
Related Publication 20200330480A1 · Oct 22, 2020